Get the Stockscreener App
2.31
0.86%
-0.02
After Hours:
2.30
-0.01
-0.43%
Tempest Therapeutics Inc stock is traded at $2.31, with a volume of 18,335.
It is down -0.86% in the last 24 hours and up +61.54% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
See More
Previous Close:
$2.33
Open:
$2.36
24h Volume:
18,335
Relative Volume:
0.07
Market Cap:
$11.38M
Revenue:
-
Net Income/Loss:
$-43.10M
P/E Ratio:
-0.2376
EPS:
-9.7212
Net Cash Flow:
$-36.82M
1W Performance:
+3.59%
1M Performance:
+61.54%
6M Performance:
-47.56%
1Y Performance:
-60.45%
1-Day Range:
$2.2856
$2.37
1-Week Range:
$2.16
$2.50
52-Week Range:
$1.20
$6.1838
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
2.31 | 11.48M | 0 | -43.10M | -36.82M | -9.7212 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-10-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
Tempest lays out strategic plan to advance recently acquired dual-targeting CAR-T assets - marketscreener.com
Tempest Therapeutics outlines plans for acquired CAR T assets - BioWorld MedTech
Tempest Therapeutics Highlights Partner-Funded CAR-T Oncology Pipeline - TipRanks
Tempest Therapeutics, Inc. Updates on Oncology Pipeline and Clinical Progress - TradingView
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets - GlobeNewswire
Key facts: Tempest Therapeutics announces management changes; issues warrants - TradingView
Tempest Therapeutics Signs Warrant Agreement With Computershare - TradingView
Tempest Therapeutics (NASDAQ: TPST) closes CAR T acquisition and names new CEO - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Tempest Therapeutics completes acquisition of CAR-T assets By Investing.com - Investing.com Nigeria
Tempest Therapeutics completes acquisition of CAR-T assets - Investing.com
Tempest Therapeutics Closes All-Stock Transaction to Acquire Next-Generation CAR-T Assets and Appoints Matt Angel as CEO - Quiver Quantitative
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets - GlobeNewswire
Cancer biotech Tempest retools around dual CAR-Ts and new CEO - Stock Titan
Tempest Therapeutics (TPST) Price Target Increased by 22.22% to 11.22 - Nasdaq
Tempest Therapeutics Announces New Leadership and Acquisition - MSN
Will Tennessee Valley Authority benefit from AI trendsMarket Sentiment Summary & Weekly High Momentum Picks - baoquankhu1.vn
What’s the outlook for Tempest Therapeutics Inc.’s sectorPortfolio Gains Report & Consistent Return Investment Signals - mfd.ru
Tempest Therapeutics (NASDAQ: TPST) wins approval for rights plan, share issuance and equity pool - Stock Titan
Investment Report: Is Tempest Therapeutics Inc stock a value trapJuly 2025 Final Week & Daily Stock Trend Watchlist - baoquankhu1.vn
Aug Decliners: Is Tempest Therapeutics Inc stock a top performer YTD2025 EndofYear Setup & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Tempest Therapeutics stock surges after H.C. Wainwright upgrade By Investing.com - Investing.com Australia
Tempest Therapeutics stock surges after H.C. Wainwright upgrade - Investing.com
H.C. Wainwright upgrades Tempest Therapeutics stock rating to Buy with $11 target - Investing.com India
HC Wainwright & Co. Upgrades Tempest Therapeutics (TPST) - Nasdaq
Inflation Data: Will Tempest Therapeutics Inc stock recover after earningsJuly 2025 Update & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Tempest Therapeutics Announces Record Date for Warrant Dividends Distribution Following Asset Purchase Agreement - Quiver Quantitative
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders - GlobeNewswire
Cancer drug developer Tempest to hand out 1:1 stock warrants - Stock Titan
How risky is Tempest Therapeutics Inc. stock nowCEO Change & Precise Buy Zone Tips - bollywoodhelpline.com
Will Tempest Therapeutics Inc. stock pay special dividendsJuly 2025 Institutional & Entry Point Confirmation Signals - bollywoodhelpline.com
Sentiment Review: Can Tempest Therapeutics Inc reach all time highs this yearPortfolio Update Report & Community Driven Trade Alerts - baoquankhu1.vn
Is Tempest Therapeutics Incs growth already priced inWeekly Trend Recap & Daily Profit Focused Screening - baoquankhu1.vn
Published on: 2026-01-13 20:12:45 - Bộ Nội Vụ
Tempest Therapeutics receives Nasdaq notice for annual meeting compliance By Investing.com - Investing.com Canada
Tempest Therapeutics Faces Nasdaq Noncompliance, Plans Annual Meeting - TipRanks
Tempest Therapeutics receives Nasdaq notice for annual meeting compliance - Investing.com India
Tempest Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Why retail investors favor Tempest Therapeutics Inc. stockJuly 2025 Chart Watch & High Win Rate Trade Tips - Улправда
Will Tempest Therapeutics Inc. stock split again soonJuly 2025 Update & Fast Momentum Stock Entry Tips - Улправда
Tempest Therapeutics, Inc.Common Stock (NQ: TPST - FinancialContent
Market Outlook: Will Tempest Therapeutics Inc stock pay special dividendsJuly 2025 Drop Watch & Real-Time Buy Signal Alerts - moha.gov.vn
Tempest Therapeutics (TPST) Stock Price, Quote, News & History - Benzinga
Will Tempest Therapeutics Inc. stock beat EPS estimatesJuly 2025 Weekly Recap & Weekly High Potential Stock Alerts - bolumsonucanavari.com
How sustainable is Tempest Therapeutics Inc. stock dividend payout2025 Winners & Losers & Verified Momentum Stock Alerts - Улправда
Tempest Therapeutics closes $4.25 million registered direct offering By Investing.com - Investing.com India
Tempest Therapeutics Closes $4.3 Million Direct Offering - MarketScreener
Tempest Therapeutics closes $4.25 million registered direct offering - Investing.com
Tempest Therapeutics : Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules - MarketScreener
Tempest Therapeutics, Inc. Completes Registered Direct Offering and Private Placement, Raising Approximately $4.25 Million - Quiver Quantitative
Tempest Announces Closing of Up To $8.35 Million Registered - GlobeNewswire
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):